miR‑501‑3p sensitizes glioma cells to cisplatin by targeting MYCN

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Research

Background:

• Cisplatin is a key chemotherapy for glioma, but chemoresistance limits its efficacy.
• MicroRNAs (miRNAs) are implicated in glioma drug resistance, yet the role of miR-501-3p remains undefined.

Purpose of the Study:

• To investigate the role of miR-501-3p in cisplatin resistance in glioma cells.
• To elucidate the underlying molecular mechanisms of miR-501-3p's function in chemoresistance.

Main Methods:

• Quantitative analysis of miR-501-3p expression in glioma tissues and cell lines.
• In vitro assays to assess the effects of miR-501-3p modulation on cell growth, invasion, and apoptosis.
• Luciferase reporter assays and RT-qPCR to identify and validate miR-501-3p targets.

Main Results:

• miR-501-3p expression was significantly decreased in glioma tissues and cisplatin-resistant cells.
• Overexpression of miR-501-3p inhibited glioma cell proliferation and invasion while promoting apoptosis.
• miR-501-3p sensitized glioma cells to cisplatin, increasing sensitivity to proliferation arrest and cell death.
• MYCN was identified as a direct target of miR-501-3p, and its restoration reversed miR-501-3p's effects.

Conclusions:

• miR-501-3p plays a crucial role in overcoming cisplatin resistance in glioma.
• The miR-501-3p/MYCN axis is a key mechanism regulating chemoresistance.
• miR-501-3p represents a potential therapeutic target and predictive biomarker for cisplatin resistance in glioma.